Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease (NCT07415018) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
United States40 participantsStarted 2026-07-22
Plain-language summary
To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with tissue confirmed solid malignancy and standard of care brain MRI with equivocal results for LMD (questionable or possible) and negative LP CSF sampling or patients with high risk clinical LMD and negative brain MR and LP CSF sampling. Initially, we will target solid tumors, but if more patients are needed to meet the study power we will enroll liquid tumors.
* Participants \> 18 years of age.
* Participants are able to consent.
Exclusion Criteria:
* Participants with CSF sampling positive for LMD or MR brain/spine with definitive evidence of LMD.
* Participants with implantable devices that can not be scanned with MR safe mode for participant safety.
* Pregnant participants or potentially pregnant participants are at risk of contrast on the fetus
Pediatric participants \< 18 years of age.
What they're measuring
1
Safety and adverse events (AEs)
Timeframe: Through study completion; an average of 1 year.